Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT.

@article{Strang2019ExtendedreleaseNV,
  title={Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT.},
  author={John Strang and Michael Kelleher and Soraya Mayet and Edward Day and Jennifer M Hellier and Sarah Byford and Caroline A. Murphy and Blair Kp McLennan and James Shearer and Elizabeth Ryan and John Marsden},
  journal={Health technology assessment},
  year={2019},
  volume={23 3},
  pages={
          1-72
        }
}
BACKGROUND People recovering from heroin addiction need better treatments than are currently offered. The chronic relapsing nature of drug dependence means that helping a patient to achieve abstinence is often difficult. Naltrexone blocks the effects of ingested heroin; however, evidence is conflicting regarding the best delivery method. OBJECTIVES The primary purpose of the trial was to evaluate the clinical effectiveness and cost-effectiveness of extended-release naltrexone versus standard… CONTINUE READING
2
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Psychosocial Interventions

NICE. Drug Misuse
  • Clinical Guideline (CG)51. London: NICE; 2007. DOI: 10.3310/hta23030 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 3 © Queen’s Printer and Controller of HMSO
  • 2019

The Medicines for Human Use (Clinical Trials

Great Britain
  • Amendment Regulations 2006. London: The Stationary Office;
  • 2006

The Medicines for Human Use (Clinical Trials) Regulation 2004: SI 2004/1031

Great Britain
  • London: The Stationery Office;
  • 2004